Publication:
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.

Loading...
Thumbnail Image

Date

2019-08-21

Authors

Vigón, Lorena
Vázquez-Morón, Sonia
Berenguer, Juan
González-García, Juan
Jiménez-Sousa, Ma Ángeles
Guardiola, Josep M
Crespo, Manuel
de Los Santos, Ignacio
Von Wichmann, Miguel A
Carrero, Ana

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.

Description

MeSH Terms

Adult
Antibodies, Neutralizing
Antirheumatic Agents
Antiviral Agents
Cell Line, Tumor
Female
Genotype
HIV Infections
Hepacivirus
Hepatitis C
Hepatitis C Antibodies
Humans
Interferon-alpha
Male
Middle Aged
Phylogeny
Retrospective Studies
Ribavirin
Sustained Virologic Response
Viral Load

DeCS Terms

CIE Terms

Keywords

Citation